Surrozen (NASDAQ:SRZN) Director Purchases 315,457 Shares of Stock

by · The Markets Daily

Surrozen, Inc. (NASDAQ:SRZN – Get Free Report) Director Tim Kutzkey purchased 315,457 shares of the business’s stock in a transaction on Thursday, November 13th. The shares were purchased at an average cost of $12.65 per share, for a total transaction of $3,990,531.05. Following the transaction, the director directly owned 962,718 shares of the company’s stock, valued at approximately $12,178,382.70. The trade was a 48.74% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Surrozen Stock Performance

Shares of NASDAQ:SRZN traded down $0.58 during midday trading on Tuesday, reaching $15.54. The company’s stock had a trading volume of 100,264 shares, compared to its average volume of 92,641. The firm has a market capitalization of $133.18 million, a price-to-earnings ratio of -0.70 and a beta of 0.62. The firm has a 50 day moving average price of $13.51 and a two-hundred day moving average price of $11.11. Surrozen, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $18.17.

Surrozen (NASDAQ:SRZN – Get Free Report) last released its earnings results on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing the consensus estimate of ($1.17) by ($2.44). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%.The business had revenue of $0.98 million for the quarter. As a group, research analysts anticipate that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Analysts Set New Price Targets

SRZN has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Surrozen to a “sell” rating in a research report on Friday. Finally, Lifesci Capital raised Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

Get Our Latest Stock Analysis on SRZN

Institutional Investors Weigh In On Surrozen

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Citadel Advisors LLC increased its position in shares of Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after acquiring an additional 3,424 shares during the last quarter. Geode Capital Management LLC boosted its position in Surrozen by 22.6% in the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after purchasing an additional 5,702 shares during the last quarter. Heights Capital Management Inc. bought a new position in Surrozen in the 1st quarter valued at $524,000. Armistice Capital LLC purchased a new stake in shares of Surrozen during the 2nd quarter valued at $536,000. Finally, Woodline Partners LP purchased a new stake in shares of Surrozen during the 3rd quarter valued at $621,000. 66.57% of the stock is owned by institutional investors.

Surrozen Company Profile

(Get Free Report)

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

Further Reading